SeaStar Medical Holding Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
49.4%projected annual EPS growth
Analyst Coverage
2analysts covering
FY Revenue (est.)
$2Mnext fiscal year
FY EPS (est.)
-$3.64next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
QUELIMMUNE Hospital Customers Quarterly17Target: Double the customer base in 2026
NEUTRALIZE-AKI Patient Enrollment Quarterly198.0
Net Product Revenue Quarterly495K
Watch Items
- Going Concern Risk and Cash RunwayTrigger: Cash balance falling below $5.0 million without a secured equity line or financing facilityAction: Evaluate dilutive impact of Lincoln Park Capital resale prospectus or alternative debt/equity financing to extend runway beyond 12 months.
- NEUTRALIZE-AKI Pivotal Trial Enrollment CompletionTrigger: Failure to complete enrollment of 339 adult patients by late 2026Action: Assess clinical trial site expansion and investigator engagement to prevent delays in the planned 2027 PMA submission.
Research as of 20 Jun 2026